Oscar Health (OSCR), Why Is This Insurer Drawing Fresh Attention?
Investor rotation into healthcare in response to tougher macro conditions has put Oscar Health (OSCR) on watch, as the insurer rides sector momentum alongside its revenue growth and expanding free cash flow margin.
Recent price action backs up that story. Oscar Health’s share price return of 12.46% over the past 90 days and 118.90% year to date, alongside a 1-year total shareholder return of 69.53% and a very large 3-year total shareholder return above 4x, points to momentum that investors are linking to both the appeal of the defensive sector and the company’s own fundamentals.
Scan beyond Oscar Health and see how other insurers and healthcare plays are reacting to the same macro rotation with our curated list of 11 resilient stocks with low risk scores.
Bulls point to Oscar Health’s revenue growth and rising free cash flow margin, while bears flag the recent surge and a value score of 2. Which story does the current valuation actually support?
Most Popular Narrative: 94.4% Undervalued
Against Oscar Health’s last close at $32.77, the most followed narrative pegs fair value at $583.34 per share, which frames a radically different pricing story.
Every so often, a ticker flashes on my screen that makes me stop and rub my eyes. It is the kind of number that look like a mistake, like you thought you were getting clothes on Christmas Day, but then your parents surprise you by hiding the PlayStation 2 you've been wanting for months in the other room...
The screen showed Oscar Health. Ridiculous name for a health insurance company, but the numbers are anything but.
Read the complete narrative. Read the complete narrative.
The narrative leans hard on aggressive long term cash flow compounding, rich profitability metrics and a premium valuation multiple that treats Oscar Health more like a high growth tech platform than a plain insurer. It explores how those assumptions back into a triple digit fair value and what kind of revenue and margin profile they imply over time.
Result: Fair Value of $583.34 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
Still, the Oscar Health story carries pressure points, including dependence on robust cash generation assumptions and sensitivity to small shifts in growth or discount rate inputs.
Find out about the key risks to this Oscar Health narrative.
Another View: Oscar Health Through The P/E Lens
A very different signal comes from a simple earnings multiple. Oscar Health trades on a P/E of 18.3x, which is richer than the US insurance sector at 11.1x, yet below its peer group average of 33.8x and also under the 21.7x fair ratio that the market could move toward.
That mix hints at a stock investors already pay up for, but not at the most optimistic level the fair ratio suggests. This raises a practical question: Is the gap to both peers and the fair ratio compensation for risk, or room for the story to keep evolving from here?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed sentiment around Oscar Health is clear, and the push and pull between 1 or more risks and 1 or more rewards will not wait. Pressure test the bullish and bearish angles for yourself by weighing these 2 key rewards and 2 important warning signs.
Looking for more investment ideas beyond Oscar Health?
If the Oscar Health setup caught your attention, do not stop here. The next move often comes from spotting fresh opportunities before everyone else notices.
- Target potential mispricing by scanning companies that combine quality fundamentals with lower valuations through our 32 high quality undervalued stocks.
- Build a more resilient portfolio by zeroing in on businesses with strong finances using the list of solid balance sheet and fundamentals (23 results).
- Hunt for underfollowed opportunities by checking out a curated 15 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com